Higher systolic blood pressure is associated with progression of carotid intima-media thickness in patients with chronic kidney disease

Kidney International

Volumn 77, Issue 9, 2010, Pages 794-800

  Kendrick, Jessica ^a   Chonchol, Michel ^a   Gnahn, Hannes ^b   Sander, Dirk ^c,d  

^a UNIVERSITY OF COLORADO   (United States)

^b INVADE Study Group   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d Medical Park Hospital   (Germany)

Author keywords

Cardiovascular events; Chronic kidney disease; Hypertension

Indexed keywords

AGED; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; COHORT ANALYSIS; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

AGED; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; RENAL INSUFFICIENCY, CHRONIC; SYSTOLE; TUNICA INTIMA; TUNICA MEDIA;

EID: 77951093070     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.557     Document Type: Article

References (45)

1. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047. (Pubitemid 350074801)
2. Meguid El Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet 2005; 365: 331-340.
3. Zoccali C. Traditional and emerging cardiovascular and renal risk factors: an epidemiologic perspective. Kidney Int 2006; 70: 26-33.
4. Vasan RS, Larson MG, Leip EP et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291-1297.
5. Levy D, Larson MG, Vasan RS et al. The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557-1562. (Pubitemid 26154241)
6. Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350: 757-764.
7. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
8. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3264.
9. Dahlof B, Lindholm LH, Hansson L et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-1285.
10. Rao MV, Qiu Y, Wang C et al. Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004. Am J Kidney Dis 2008; 51(4 Suppl 2): S30-S37. (Pubitemid 351444715)
11. Sarafidis PA, Li S, Chen SC et al. Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med 2008; 121: 332-340.
12. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
13. Weiner DE, Tighiouart H, Levey AS et al. Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease. J Am Soc Nephrol 2007; 18: 960-966.
14. Berl T, Hunsicker LG, Lewis JB et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005; 16: 2170-2179.
15. Hollander M, Hak AE, Koudstaal PJ et al. Comparison between measures of atherosclerosis and risk of stroke: the Rotterdam Study. Stroke 2003; 34: 2367-2372.
16. Blacher J, Pannier B, Guerin AP et al. Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease. Hypertension 1998; 32: 570-574.
17. Benedetto FA, Mallamaci F, Tripepi G et al. Prognostic value of ultrasonographic measurement of carotid intima media thickness in dialysis patients. J Am Soc Nephrol 2001; 12: 2458-2464.
18. Desbien AM, Chonchol M, Gnahn H et al. Kidney function and progression of carotid intima-media thickness in a community study. Am J Kidney Dis 2008; 51: 584-593.
19. Shlipak MG, Katz R, Kestenbaum B et al. Clinical and subclinical cardiovascular disease and kidney function decline in the elderly. Atherosclerosis 2009; 204: 298-303.
20. Chonchol M, Gnahn H, Sander D. Impact of subclinical carotid atherosclerosis on incident chronic kidney disease in the elderly. Nephrol Dial Transplant 2008; 23: 2593-2598.
21. Sander D, Schulze-Horn C, Bickel H et al. Combined effects of hemoglobin A1c and C-reactive protein on the progression of subclinical carotid atherosclerosis: the INVADE study. Stroke 2006; 37: 351-357.
22. Kablak-Ziembicka A, Przewlocki T, Tracz W et al. Diagnostic value of carotid intima-media thickness in indicating multi-level atherosclerosis. Atherosclerosis 2007; 193: 395-400.
23. de Groot E, van Leuven SI, Duivenvoorden R et al. Measurement of carotid intima-media thickness to assess progression and regression of atherosclerosis. Nat Clin Pract Cardiovasc Med 2008; 5: 280-288.
24. London GM, Guerin AP, Marchais SJ et al. Cardiac and arterial interactions in end-stage renal disease. Kidney Int 1996; 50: 600-608.
25. Chambless LE, Folsom AR, Davis V et al. Risk factors for progression of common carotid atherosclerosis: the Atherosclerosis Risk in Communities Study, 1987-1998. Am J Epidemiol 2002; 155: 38-47.
26. van der Meer IM, Iglesias del Sol A, Hak AE et al. Risk factors for progression of atherosclerosis measured at multiple sites in the arterial tree: the Rotterdam Study. Stroke 2003; 34: 2374-2379.
27. O'Leary DH, Polak JF, Kronmal RA et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14-22.
28. Kocaman O, Oflaz H, Yekeler E et al. Endothelial dysfunction and increased carotid intima-media thickness in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2004; 43: 854-860.
29. Szeto CC, Chow KM, Woo KS et al. Carotid intima-media thickness predicts cardiovascular diseases in Chinese predialysis patients wth chronic kidney disease. J Am Soc Nephrol 2007; 18: 1966-1972.
30. Hsia J, Margolis KL, Eaton CB et al. Prehypertension and cardiovascular disease risk in the women's health initiative. Circulation 2007; 115: 855-860.
31. Pohl MA, Blumenthal S, Cordonnier DJ et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the Irbesartan Diabetic Nephropathy Trial: clinical implications and limitations. J Am Soc Nephrol 2005; 16: 3027-3037.
32. Pickering TG, Hall JE, Appel LJ et al. Recommendations for Blood Pressure Measurement in Humans and Experimental Animals. Part 1: Blood Pressure Measurement in Humans: A Statement for Professionals From the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005; 45: 142-161.
33. Benjo A, Thompson RE, Fine D et al. Pulse pressure is an age-independent predictor of stroke development after cardiac surgery. Hypertension 2007; 50: 630-635.
34. Klassen PS, Lowrie EG, Reddan DN et al. Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA 2002; 287: 1548-1555.
35. Sander D, Kukla C, Klingelhofer J et al. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: a 3-year follow-up study. Circulation 2000; 102: 1536-1541.
36. Burke GL, Evans GW, Riley WA et al. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study. Stroke 1995; 26: 386-391.
37. Bostom AG, Kronenberg F, Ritz E. Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol 2002; 13: 2140-2144.
38. Levey AS, Coresh J, Balk E et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-147.
39. Dubois D, Dubois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Int Med 1916; 17: 863-871.
40. Norgren L, Hiatt WR, Dormandy JA et al. Inter-society consensus for the management of peripheral arterial disease. Int Angiol 2007; 26: 81-157.
41. Alpert JS, Thygesen K, Antman E et al. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36: 959-969.
42. Adams H, Adams R, Del Zoppo G et al. Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke 2005; 36: 916-923.
43. Walser M. Assessing renal function from creatinine measurements in adults with chronic renal failure. Am J Kidney Dis 1998; 32: 23-31.
44. Vester B, Rasmussen K. High performance liquid chromatography method for rapid and accurate determination of homocysteine in plasma and serum. Eur J Clin Chem Clin Biochem 1991; 29: 549-554.
45. Tseng CK, Marquez VE, Fuller RW et al. Synthesis of 3-deazaneplanocin A, a powerful inhibitor of S-adenosylhomocysteine hydrolase with potent and selective in vitro and in vivo antiviral activities. J Med Chem 1989; 32: 1442-1446.